Roivant Sciences Ltd.
ROIV
$20.81
-$0.06-0.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -113.52M | -223.36M | -206.48M | 169.38M | -230.18M |
| Total Depreciation and Amortization | 921.00K | 1.10M | 8.16M | 1.94M | 1.92M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -80.14M | 55.04M | -8.74M | -325.47M | -48.85M |
| Change in Net Operating Assets | 7.08M | -37.17M | 34.48M | -53.11M | 10.31M |
| Cash from Operations | -185.66M | -204.38M | -172.57M | -207.25M | -266.81M |
| Capital Expenditure | -7.85M | -4.04M | -811.00K | -1.83M | -996.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 74.93M | 154.44M | 110.39M |
| Other Investing Activities | 128.27M | -1.08B | 1.00B | 301.46M | -3.40B |
| Cash from Investing | 120.42M | -1.09B | 1.07B | 454.07M | -3.29B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | -49.09M | -1.83M |
| Issuance of Common Stock | 69.07M | 30.06M | 12.97M | 28.12M | 7.27M |
| Repurchase of Common Stock | -6.48M | -217.83M | -302.91M | -251.98M | -114.51M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 112.78M | -- | -- |
| Cash from Financing | 62.59M | -187.77M | -177.15M | -272.95M | -109.07M |
| Foreign Exchange rate Adjustments | 1.21M | 815.00K | -489.00K | -1.07M | 5.04M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.45M | -1.48B | 723.99M | -27.20M | -3.66B |